4d agoSeeking AlphaBEARISH 32General
Amgen slides 10% amid olpasiran read-through concerns
Amgen stock fell 10% after Novartis’ pelacarsen Phase 3 failure raised olpasiran concerns.
Archived explainer. For the current picture see today's AMGN page.
Why Is AMGEN INC (AMGN) Stock Down Today?
By the Top Tier Newswire AI Desk · September 9, 2026 at 12:20 AM ET · reviewed against 19 wire stories
AMGEN INC (AMGN) is down -10.08% in the latest session. Our newswire has captured 19 stories on AMGN across 11 sources in the last 36 hours, with AI sentiment reading mixed (avg 48/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Amgen Inc (AMGN) shares fell 10.08% to $393.17 in a session marked by investor concern over the future of its cholesterol-lowering drug olpasiran. The decline followed Novartis’ announcement of a failed Phase 3 trial for its competing drug pelacarsen, which raised doubts about the broader Lp(a) drug class. Despite Amgen releasing positive results from a late-stage lung cancer trial with AstraZeneca, the market focused on the negative implications for its cholesterol portfolio.
What Happened
The primary driver of the sell-off was Novartis’ Phase 3 trial failure for pelacarsen, which has created uncertainty about olpasiran’s potential. Amgen’s stock dropped significantly as investors reevaluated the risk of regulatory or commercial setbacks for its high-conviction asset. The market also appeared to discount Amgen’s positive lung cancer data, which showed that its drug Imdelltra in combination with AstraZeneca’s Imfinzi extended survival in a late-stage trial. However, this news could not offset the broader negative sentiment. BMO Capital Markets also downgraded Amgen following the Novartis news, adding pressure to the stock. The session saw heightened volatility, with Amgen shares falling to a 52-week low of $395.11 after an 8-session decline of 10.1%.
What The Data Shows
The stock’s intraday performance reflected a sharp sell-off, with volume expected to exceed its 30-day average. Over the past 30 days, sentiment has deteriorated from an average of 55/100 to 48/100. Recent insider transactions show three executives sold a combined $4.1 million in shares over the last 90 days. On the 52-week tape, the stock printed 42 fresh 52-week lows but also one fresh high on 2026-09-08. Congressional trades also included several sales of AMGN shares, with the most recent disclosed on 2026-09-05.
What To Watch
Investors will look to Amgen’s upcoming corporate actions, including its dividend schedule set for ex-dividend on 2026-08-21. The focus will remain on olpasiran’s regulatory path and how the market reacts to further data or competitor developments in the Lp(a) space.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
AMGN by the numbers
Last: $393.17Session: -10.08%7 sessions: -9.46%Coverage: 19 stories / 11 sourcesAI sentiment: 48/100 (mixed)Mkt cap: $236.4BP/E: 27.252w: $269.77 to $447.03
The headlines behind the move
4d agoReutersBULLISH 73Product/PR
Amgen-AstraZeneca drug combo helps lung cancer patients live longer in late-stage study
4d agoSeeking AlphaBEARISH 38Product/PR
Amgen: Why Rivals' Cholesterol Drug Fail Is Bad News For The Pharma (Rating Downgrade)
Amgen (AMGN) drops after Novartis’ pelacarsen Phase 3 miss, pressuring olpasiran’s thesis amid patent cliffs. Click here to read my most recent analysis.
4d agoYahoo TopBEARISH 28General
Amgen Falls 10% as Novartis Trial Failure Clouds a Cholesterol Drug Class; NVS Stock Drops 14%
Novartis just handed the entire Lp(a) drug class a failing grade, and Amgen is taking the worst of the punishment despite releasing promising trial results of its own on the very same morning.
4d agoSeeking AlphaBULLISH 73Product/PR
Amgen, Astra drug combo extends survival in late-stage trial for lung cancer
Amgen (AMGN) announces success in a late-stage trial testing its lung cancer therapy Imdelltra with AstraZeneca
4d agoCNBCNEUTRAL 50General
Stocks making the biggest moves midday: Amgen, Qualcomm, Expedia, CoreWeave & more
Here are some of the companies making headlines in midday trading.
4d agoSeeking AlphaBEARISH 34General
Amgen drops on Novartis trial setback for heart therapy; BMO downgrades
Amgen (AMGN) stock drops after a phase 3 trial failure for a heart drug from Novartis (NVS) and Ionis Pharma (IONS). BMO Capital Markets downgrades. Read more here.
4d agoYahoo TopBEARISH 42General
Stocks to Watch: Amgen, Nike, Rigetti; Bloom Energy
↘️ Amgen (AMGN): Shares of the biotechnology company, a major contributor to the Dow, shed more than 8%. The move came after the Swiss drugmaker Novartis (CH:NOVN) said late Friday that
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on AMGN: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier AMGN move explainers: 2026-09-09 · 2026-09-08 · 2026-08-31